Literature DB >> 17148703

Prevention of venous thromboembolism in medically ill patients: a clinical update.

Alexander G G Turpie1, Alain Leizorovicz.   

Abstract

The risk of venous thromboembolism (VTE) in hospitalised medically ill patients is often underestimated, despite the fact that it remains a major cause of preventable morbidity and mortality in this group. It is not well recognised that the risk of VTE in many hospitalised medically ill patients is at least as high as in populations after surgery. This may partly be attributed to the clinically silent nature of VTE in many patients, and the difficulty in predicting which patients might develop symptoms or fatal pulmonary embolism. Two large studies, Prospective Evaluation of Dalteparin Efficacy for Prevention of VTE in Immobilized Patients Trial and prophylaxis in MEDical patients with ENOXaparin, have shown that low-molecular-weight heparins provide effective thromboprophylaxis in medically ill patients, without increasing bleeding risk. Recent guidelines from the American College of Chest Physicians recommend that acutely medically ill patients admitted with congestive heart failure or severe respiratory disease, or those who are confined to bed and have at least one additional risk factor for VTE, should receive thromboprophylaxis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17148703      PMCID: PMC2653926          DOI: 10.1136/pgmj.2005.044107

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  34 in total

Review 1.  Risk of and prophylaxis for venous thromboembolism in hospital patients. Thromboembolic Risk Factors (THRIFT) Consensus Group.

Authors: 
Journal:  BMJ       Date:  1992-09-05

2.  Heparin prophylaxis in bedridden patients.

Authors:  J F Bergmann; C Caulin
Journal:  Lancet       Date:  1996-07-20       Impact factor: 79.321

Review 3.  The changing pattern of venous thromboembolic disease.

Authors:  A T Cohen; R A Edmondson; M J Phillips; V P Ward; V V Kakkar
Journal:  Haemostasis       Date:  1996 Mar-Apr

Review 4.  Low-molecular-weight heparins and unstable angina--current perspectives.

Authors:  A G Turpie
Journal:  Haemostasis       Date:  1997

Review 5.  Prevention of venous thromboembolism in cancer using low-molecular-weight heparins.

Authors:  A K Kakkar; R C Williamson
Journal:  Haemostasis       Date:  1997

Review 6.  Noninvasive diagnosis of deep venous thrombosis. McMaster Diagnostic Imaging Practice Guidelines Initiative.

Authors:  C Kearon; J A Julian; T E Newman; J S Ginsberg
Journal:  Ann Intern Med       Date:  1998-04-15       Impact factor: 25.391

7.  High risk of the critically ill for venous thromboembolism.

Authors:  J F Cade
Journal:  Crit Care Med       Date:  1982-07       Impact factor: 7.598

8.  Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.

Authors:  Alain Leizorovicz; Alexander T Cohen; Alexander G G Turpie; Carl-Gustav Olsson; Paul T Vaitkus; Samuel Z Goldhaber
Journal:  Circulation       Date:  2004-08-02       Impact factor: 29.690

9.  A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis.

Authors:  Samuel Z Goldhaber; Victor F Tapson
Journal:  Am J Cardiol       Date:  2004-01-15       Impact factor: 2.778

10.  Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. The Heparin Prophylaxis Study Group.

Authors:  B Gärdlund
Journal:  Lancet       Date:  1996-05-18       Impact factor: 79.321

View more
  1 in total

1.  Clinicians adopting evidence based guidelines: a case study with thromboprophylaxis.

Authors:  Nicola H Chapman; Steven P Lazar; Margaret Fry; Marissa N Lassere; Beng H Chong
Journal:  BMC Health Serv Res       Date:  2011-09-28       Impact factor: 2.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.